Press "Enter" to skip to content

Doctor who developed a tetanus vaccine, human experiments will be started on Covid-19 vaccine – Health News


In Turkey, during the 1990s in the work involved in vaccine development and for the first time ‘adsorbed tetanus’ at the beginning of the team that developed the vaccine, Dr. Erkan Özcengiz developed a local vaccine against Covid-19 within Pharmada İlaç.

Animal experiments of ‘Sars-CoV-2 Recombinant Protein Subunit Vaccine’ in studies conducted since August have been positive at the beginning of January.

Speaking about the vaccine, which will be passed on to human experiments, Özcengiz said that they developed ‘Sars-CoV-2 Recombinant Protein Subunit Vaccine’ against Covid-19.

Özcengiz said, “In the studies, a very effective and harmless vaccine prototype has been formed. This vaccine contains 3 important proteins belonging to the Sars-CoV-2 virus. These antigens are expressed in the microorganism, purified and strengthened with a very suitable adjuvant formulation. The results we obtained here are also the humoral immune response. and a strong cellular immune response was obtained. Now we have targets for the production of this recombinant protein vaccine in our country and all over the world.

“WE ARE PLANNING IT TO BE READY TO USE IN THE FALL”

Stating that they have made a GMP (Good manufacturing practice) application to the Ministry of Health for the production site, Dr. Özcengiz said, “We will publish our first scientific studies on the vaccine in the near future. The vaccine produces a strong immune response and antibody response. We plan to use an antigen compatible with the variants emerging as soon as possible to the vaccine and use it as another vaccine in human studies. The support of the Ministry of Health is very important in human studies. The rapid progress of the studies there is a phase 1 human group. “We plan to make phases 2 and 3 together and make this vaccine ready for use in the autumn. At the same time, we aim to emerge as a vaccine that is compatible with variants and is strengthened.”

“WE THINK IT WILL BE VERY EFFECTIVE IN THE ELDERLY”

Dr. Özcengiz stated that the production capacity of the vaccine will be clarified in the first large production study, and that they aim to meet the need for vaccines, especially in countries that cannot reach the vaccine, by reaching a very good capacity. Emphasizing the importance of vaccines to respond with strong immunity, to respond long, to be effective and harmless, Özcengiz said, “Here, the quality of vaccines is much more important especially for the immune response in elderly people. Because the target group of this virus is mainly for the elderly and the age group Because the immune system is weakened due to aging and this virus does not receive a rapid cellular immune response immediately in the initial phase of the infection, this infection may go to the more severe transition points as the age progresses. Therefore, our goal is that this vaccine will be very effective in the elderly. we think, “he said.

Download the NTV application, stay up to date

HOW DOES THE CORONA VIRUS AFFECT THE BRAIN?


Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *